2012年敦煌市恶性肿瘤发病与死亡分析

An analysis of cancer incidence and mortality in Dunhuang city of 2012

目的:分析2012年敦煌市肿瘤登记地区恶性肿瘤发病与死亡情况,为政府制定肿瘤防控措施提供科学依据。方法:利用2012年敦煌市肿瘤登记报告资料,分析敦煌市恶性肿瘤的发病率和死亡率,中国及世界人口标化率。结果:2012年敦煌市肿瘤登记处报告恶性肿瘤新发病例305例(男性157例,女性148例),发病率为212.72/10万(男性218.50/10万,女性206.91/10万);中标率为167.06/10万(男性175.77/10万,女性158.50/10万),恶性肿瘤死亡病例109例(男性67例,女性42例),死亡率为76.02/10万(男性93.24/10万,女性58.72/10万),中标率为61.24/10万(男性78.68/10万,女性44.53/10万)。2012年敦煌市肿瘤登记处恶性肿瘤发病第1位的是乳腺癌,其次为胃癌、肺癌、食管癌和结直肠癌,前5位恶性肿瘤占全部恶性肿瘤的60.98%;恶性肿瘤死亡第1位的是胃癌,其次为肺癌、肝癌、食管癌和胰腺癌,前5位恶性肿瘤占全部恶性肿瘤的72.48%。结论:胃癌、食管癌、肺癌、乳腺癌、结直肠癌是敦煌市恶性肿瘤的高发癌种,应作为今后恶性肿瘤防治工作的重点,同时应进一步强化肿瘤登记报告工作。

Objective: To investigate the cancer incidence and mortality in Dunhuang cancer registry area, 2010, and to provide basisfor making control measures and strategies for prevention. Methods: The data of 2012 from Dunhuang Cancer Registries were collected and an-alyzed. Crude rate,age-standardized rate,age-specific and region-specific incidence/mortalitywere calculated. Results: A total of 305 newcancer cases were reported in2012(males 157,female 148). The crude incidence was 212.72/105(males 218.50/105,female 206.91/105),andage-standardized incidence by Chinese standard population was 167.06/105(males 175.77/105,female 158.50/105). There were109 reportedcancer death cases in 2012(males 67,female 42),The crude mortality was 76.02/10/105(males 93.24/105,female 58.72/105),and age-standard-ized mortality by Chinese standard population was 61.24/105(males 78.68/105,female 44.53/105). The top 5 incidence cancers were breast can-cer,gastric cancer,lung cancer,esophageal cancer,colorectal cancer,which accounted for 60.98% ofall new cancer cases. The top 5 mortalitycancers were gastric cancer,lung cancer,liver cancer,esophageal cancer,pancreatic cancer,which accounted for 72.48% of all death cancercases.Conclusion: Gastric cancer, esophageal cancer, lung cancer, breast cancer, colorectal cancer is a high incidence of cancer, malignant tu-mor prevention and treatment of emphasis in the future should be, at the same time, should further strengthen the tumor registration report.